Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as rhuFab V2 (ranibizumab)
rhuFab V2 · 6 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| rhuFab V2 (ranibizumab) | DRUG | - |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥ 50 years * Subfoveal CNV secondary to AMD, with evidence of recent disease progression, as defined by any of the following (lesion is eligible if it meets any one of the following criteria): ≥ 5 letters (or ≥ 1 Snellen line) of BCVA lost wi...
rhuFab V2 is used for age-related macular degeneration and the choroidal neovascularization that can accompany it, a condition also described as age-related maculopathy. It is an ophthalmology monoclonal antibody developed by Roche Holding AG. The clinical program enrolled adults aged 50 years and older with these neovascular eye conditions.
rhuFab V2 is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the clinical trial program for the drug in neovascular age-related macular degeneration and related choroidal neovascularization.
rhuFab V2 is in Phase 1 development and is investigational. Its registered trials were conducted as Phase 3 studies, and all four of those trials are now completed, with no active trials listed. The program enrolled approximately 5,000 participants across its studies.
Four completed trials are registered for rhuFab V2: NCT00251459, NCT00095433, NCT00090623, and NCT00061594. NCT00251459 was the largest, enrolling 5,000 participants with choroidal neovascularization secondary to age-related macular degeneration. NCT00061594 compared rhuFab V2 with verteporfin photodynamic therapy in subfoveal neovascular macular degeneration.
Yes, rhuFab V2 is also known as ranibizumab. The two names refer to the same monoclonal antibody, and the registered trials use both names, including studies titled with rhuFab V2 and one titled with ranibizumab in choroidal neovascularization secondary to age-related macular degeneration.
The rhuFab V2 trials were randomized and enrolled adults aged 50 years and older with macular degeneration or choroidal neovascularization. NCT00061594 was an active comparison against verteporfin photodynamic therapy, while the other registered studies were uncontrolled. The trials were conducted in the United States and several other countries, including Australia, Czechia, France, Germany, and Hungary.